

Efficacy of Bovine Colostrum in The Treatment of Acute Diarrhoea in Infants and Children

Hira Hameed¹, Aummara Rafique², Nadia Tariq³, Rubina Zulfiqar⁴, Sohail Aslam⁵, Ainur Zholdabekova⁶

1. Assistant Professor, IMDC/ANTH 2,6. Senior Registrar, IMDC/ANTH 3,4. Professor, IMDC/ANTH 5. Associate Professor, IMDC/ANTH.

Corresponding author: Dr. Nadia Tariq, nadia.tariq@imdcollge.edu.pk

Abstract

Objective: The objective of this study was to determine the efficacy of bovine colostrum for the treatment of acute diarrhoea among infants and children admitted to a tertiary care hospital in Islamabad, Pakistan.

Methods: This interventional study was conducted at a tertiary care hospital, Islamabad. Infants and children admitted to the hospital with acute diarrhoea were selected through consecutive sampling. Group A received bovine colostrum along with the standard treatment, whereas group B received standard treatment alone. Number of days to achieve defecation frequency of ≤ 3 Times per day, normal stool consistency, and duration of hospital stay were the main outcomes of interest. SPSS version 21 was used for statistical analysis.

Result: Mean recovery time in Group A was 1.4865 ± 0.506 days and in Group B was $1.2174 \pm$ days. The mean number of days remaining for patients admitted in Group A was 3.8919 ± 1.629 days, while in Group B it was 3.8261 ± 1.64 days. The efficacy was 33.59 in group A, while 25.52 in group B. This difference was not statistically significant ($p=0.738$).

Conclusion: There was no difference between the group taking standard treatment and the one taking standard treatment plus bovine colostrum in terms of recovery time and efficacy but the difference was significant in terms of the number of days patients remained admitted where bovine colostrum group had increased no of days of admission so conclusion is there is not much role of bovine colostrum in treatment of acute diarrhea when combined with standard care.

Keywords: Children, Colostrum, Defecation, Diarrhoea, Hospitalised

Introduction

Diarrhoea is one of the main public health problems in infants and toddlers, especially in low-resource settings.¹ Diarrhoea can be due to viral, bacterial, parasitic and fungal infections, with viral infections being the most common aetiology.² According to WHO, it is a condition manifested as the passing of ≥ 3 loose stools/ day or too frequent stools for an individual.³ Annual reported deaths from diarrhoea are 525,000 per year.⁴

Despite Oral Rehydration Therapy's proven efficacy and advocacy by AAP (American Academy of Paediatrics), CDC (Centres for Disease Control and Prevention), WHO (World Health Organisation) and European Society for Pediatric Gastroenterology and Nutrition, only 33% of children with diarrhoea receive ORT.⁵ The efficacy of certain other therapeutic agents has also been established in preventing and treating diarrheal diseases. It is important to develop a therapeutic method that is safe and effective, and, along with the standard treatment, accelerates the recovery time and reduces the length of hospital stay.⁶⁻⁸

Colostrum contains growth factors, immunoglobulins and antimicrobial peptides. It is known to boost neonatal immunogenic defence.⁹ Bovine colostrum is commercially available colostrum abstract containing antibodies against bacterial, fungal, parasitic and viral infections.¹⁰ Use of colostrum in treating various illnesses dates back thousands of years: There are published studies that have reported efficacy in children for the treatment of acute diarrhoea. WHO or the FDA have not recommended any specific dose. Most clinical trials have reported very few minor side effects, and generally, bovine colostrum is tolerated well. The frequently associated side effects are sensitivity to milk proteins and lactose intolerance.¹¹ Therefore, possibly nutraceutical approach of bovine colostrum will improve the treatment of diarrhoea patients.¹²

Contributions:

HM, AR, RZ, SA, AZ - Conception, Design
NT, - Acquisition, Analysis, Interpretation
HM, AR - Drafting
NT, RZ, SA, AZ - Critical Review

All authors approved the final version to be published & agreed to be accountable for all aspects of the work.

Conflicts of Interest: None

Financial Support: None to report

Potential Competing Interests: None to report

Institutional Review Board Approval

No. 89/IMDC/IRB-2022

01-09-2022

Islamabad Medical & Dental College

Review began 30/12/2024

Review ended 06/03/2025

Published 29/09/2025

© Copyright 2025

Hameed et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY-SA 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



How to cite this article: Hameed H, Rafique A, Nadia Tariq, Zulfiqar R, Aslam S, Zholdabekova A. Efficacy of Bovine Colostrum in The Treatment of Acute Diarrhea in Infants and Children. JRM. 2025 Sep. 29;29(3). <https://doi.org/10.37939/jrmc.v29i3.2803>

Though studies are being conducted to determine the efficacy of certain adjuvant therapies along with the standard treatment. However, there is a dearth of literature both nationally and internationally on the efficacy of BC in the treatment of acute diarrhoea. In particular, our search has revealed that no study is available from Pakistan; therefore, this randomised controlled trial is planned. To determine the efficacy of bovine colostrum for the treatment of acute diarrhoea among infants and children admitted to a tertiary care hospital in Islamabad, Pakistan.

The bovine colostrum, in addition to the standard treatment, is more effective as compared to the standard treatment alone in infants and children aged less than 5 years.

Operational Definitions

Acute Diarrhoea is defined as a diarrheal illness of less than 7 days duration presenting with 4 or more watery loose stools per day.

Efficacy is measured in terms of recovery time and length of hospital stay.

Recovery time is assessed by the number of days needed to achieve defecation frequency ≤ 3 times/day

Materials And Methods

This interventional study was conducted at Akbar Niazi Teaching Hospital for six months after approval of the synopsis on infants and children admitted to the hospital with acute diarrhoea. A non-probability consecutive sampling was conducted.

The Open Epi sample size calculator was used for the estimation of sample size, taking a confidence interval of 95%, power 80%, ratio of sample size 1:1, mean length of hospital stay in treatment group 2.89 ± 0.78 days,¹⁴ mean length of hospital stay in control group 3.94 ± 1.53 days.¹³ The total estimated sample size came out to be 42, i.e., 21 in each group.

Children between 6 months to 5 years of any gender with acute diarrhoea were included in the study.

Children with severe malnutrition receiving medication such as antibiotics, anti-parasite, antiviral, antifungal, and or symptomatic drugs for acute diarrhoea, those Acute diarrhoea that lasted for >48 hours and Non-consenting parents/guardians were excluded from the study.

The study was conducted after getting approval from the ethical review committee of Islamabad Medical and Dental College. All patients meeting the inclusion criteria were enrolled. All patients were randomly divided into two groups through a lottery method. Group A received bovine colostrum along with the standard treatment, whereas group B received standard treatment alone. The baseline characteristics, such as patients' age, weight, gender, residence, and number of days diarrhoea before admission, were noted in a pre-structured proforma. Clinical characteristics such as fever were noted. Number of days to achieve defecation frequency of <3 Times per day, normal stool consistency, and duration of hospital stay were the main outcomes of interest.

SPSS version 21 was used for statistical analysis. Normality of the data was assessed by plotting a histogram for individual variables. Mean $\pm$ SD was reported for quantitative variables like age, current weight, number of days diarrhoea before admission, number of days to achieve defecation frequency of <3 Times per day, normal stool consistency, and duration of hospital stay. Frequency and percentages were computed for socio-demographic variables. Mann-Whitney U test was used to see the mean difference of the number of days to achieve defecation frequency of <3 Times per day, normal stool consistency, and duration of hospital stay in the treatment versus control group. Fisher's exact test was used to find the association between the treatment group and weight. The p-value of ≤ 0.05 was considered significant.

The study was conducted by all the ethical guidelines. No personal or confidential information, including the photograph, was obtained. No risk was reported with the use of bovine colostrum in the intervention arm. The data was password-protected.

Results

In our study sample, 15% (n=9) of the participants were 6 months to less than 1 year old, 41.7% (n=25) were 1-3 years old, and 43.3% (n=26) were more than 3 to 5 years old. Males were 53.3% (n=32) and females 46.7% (n=28). Participants included in the first group (A) were 61.7% (n=37) and in the second (B) 38.3% (n=23). Mean recovery time in Group A was 1.4865 ± 0.506 days, and in Group B was $1.2174 \pm$ days. The mean number of days needed to achieve defecation frequency < 3 times/ day in Group A was 2.8919 ± 1.62 days, while in Group B it was 2.5652 ± 1.532 days. The mean number of days patients remained admitted in Group A was 3.8919 ± 1.629 days, while in Group B it was 3.8261 ± 1.64 days. 18.9% (n=7) of children in group A and 17.3% (n=4) in group B had a weight less than the 5th centile. Children with weights between the 5th to 95th centile were 75.6% (n=28) in group A and 78.2% (n=18) in group B, while only 5.40% (n=2) children in group A and 4.3% (n=1) in group B were at the 95th centile. The data was not normally distributed.

The mean rank of the number of days needed to achieve defecation frequency < 3 times per day was 31.93 and 28.20 in group A and B, respectively, with no statistically significant difference between the two groups (p=0.409). The mean rank of recovery time < 3 days plus hospital stay < 3 days was 33.59 in group A, while 25.52 in group B.

This difference was statistically significant ($p=0.039$). The mean rank for the number of days the patient remained admitted was 31.05 for group B and 29.61 for group A, with no significant difference. ($p=0.738$). There was no significant difference in the weight of children between the two groups ($p=0.969$).

Table 1: Age & Gender Distribution of the Participants

Variables	Frequency (n)	Percentage (%)
Age		
6 months-<1 year	9	15
1-3 years	25	41.7
>3-5 years	26	43.3
Gender		
Males	32	53.3
Females	28	46.7

Table 2: Recovery Time, No of Days of Admission and Efficacy

Variable	Treatment Groups	Mean Rank	P value
Recovery time (number of days needed to achieve defecation frequency ≤ 3 times/day)	Group A	31.93	0.409
	Group B	28.20	
The number of days the patient remained admitted	Group A	33.59	0.039*
	Group B	25.52	
Efficacy (recovery time plus no of days the patient remained admitted)	Group A	31.05	0.738
	Group B	29.61	

Table 3: Cross Tabulation Between Treatment & Weight of Children

Treatment	Weight			P value
	Less than 5 th Centile	Between 5 th to 95 th Centile	Above 95 th Centile	
Group A	7	28	2	0.96
Group B	4	18	1	

Discussion

The first-formed milk in cows after birth is known as bovine colostrum (BC), which is nutritionally significant and may be used as a supplement in humans and other species to promote a healthy gut. According to various studies, BC, if given at a proper time, in adequate levels and at an optimal age, can be both safe and effective.¹⁴ Treatment with bovine colostrum and associated reductions in the frequency and occurrence of stools in comparison to the placebo have been established by a meta-analysis of randomised control trials conducted by Li et al. The studies included in meta-analysis had various outcomes of interest such as frequency of diarrhea, complications of diarrhea, intestinal permeability etc.¹⁵ None of the studies compared no of days needed to achieve reduced frequency which was the main outcome of interest in our study that reported no significant difference in reducing frequency of defecation between the group receiving standard treatment for diarrhea and the one with supplemental bovine colostrum.

Another meta-analysis revealed no effect of colostrum, whether bovine or human, on the occurrence of severe necrotising enterocolitis, all-cause mortality & feed intolerance as compared to placebo, but mean days to reach full enteral feed were significantly reduced in the intervention group.¹⁶ In a study conducted on preterm infants, use of bovine colostrum has been linked to fewer episodes of sepsis and reduction in length of stay in the hospital as compared to the control group, with the possible explanation of modulating the immune system, enhancing mucosal integrity, tissue repair and reducing gut inflammation.¹⁷ No significant difference was reported in reducing the length of stay between the bovine colostrum group with standard treatment and standard treatment alone in this study. It has been well-established that colostrum is effective in preventing gastrointestinal and respiratory infections based on multiple observational cohort studies, including studies done on children with co-existing health problems, such as allergies or immunodeficiencies. The past reports in the field of Paediatrics present very promising data and hypothesise the effectiveness of BC. Colostrum Supplementation may have a positive effect on the general physical health. Although bovine colostrum has a few benefits nutritionally when given in small doses, as it contains a good amount of some vitamins, minerals and micronutrients, as well as all essential amino acids, which may enhance immunity and aid in replenishing the body's resources.¹⁸

The colostrum of most species has a good composition of growth factors and immune components in comparison to the mature milk, with a maximum of these components being well preserved in human, bovine and porcine milk. They are considered to be the principal transfer of passive immunity. A major segment of protein in the colostrum is represented by immunoglobulins, with the main immune components, including the isotypes IgG, IgA, IgM, and IgD and their subclasses (IgG1-4 and IgA1-2). Human colostrum is IgA dominant, whereas bovine and porcine colostrum are IgG dominant. There are significant differences in the

composition of these isotypes in human, bovine, and porcine colostrum. Secretory IgA characterises 90% of total immunoglobulin in humans compared with BC, where IgA is only 10% of total immunoglobulins.¹⁴

A meta-analysis showed that bovine colostrum reduced the incidence of diarrhoea, positive pathogen detection and frequency of stool by once per day. The meta-analysis included a study in which children with diarrhoea were administered bovine colostrum, and in another two studies, hyperimmune bovine colostrum, or immunoglobulin from hyperimmune BC. Hyperimmune BC had a significant effect on reducing diarrhoea occurrence.¹⁹ Feeding intolerance, necrotising enterocolitis, late-onset sepsis and pre-term neonatal mortality have been reported to be reduced with colostrum feeding. It also prevents prolonged exercise-induced immunodepression in athletes, reduces vomit frequency and duration and diarrhoea episodes in children 6 months to 2 years old, along with protection against the development of diarrhoea and reduction of abdominal pain complaints in healthy volunteers.²⁰

Conclusions

There was no difference between the group taking standard treatment and the one taking standard treatment plus bovine colostrum in terms of recovery time and efficacy but the difference was significant in terms of the number of days patients remained admitted where bovine colostrum group had increased no of days of admission so conclusion is there is not much role of bovine colostrum in treatment of acute diarrhea when combined with standard care. More studies are needed to support our conclusion

References

1. Ugboko HU, Nwinyi OC, Oranusi SU, Oyewale JO. Childhood diarrhoeal diseases in developing countries. *Heliyon*. 2020 Apr 13;6(4):e03690. <https://doi.org/10.1016/j.heliyon.2020.e03690>. Erratum in: *Heliyon*. 2020;6(6):e04040.
2. Barakat SH, Meheissen MA, Omar OM, Elbana DA. Bovine colostrum in the treatment of acute diarrhoea in children: A double-blinded randomised controlled trial. *Journal of Tropical Pediatrics*. 2020 Feb;66(1):46-55. <https://doi.org/10.1093/tropej/fmz029>
3. Yu M, Jin X, Liang C, Bu F, Pan D, He Q, et al. Berberine for diarrhea in children and adults: a systematic review and meta-analysis. *Therapeutic Advances in Gastroenterology*. 2020 Oct; 13:1756284820961299.
4. Claudine U, Kim JY, Kim EM, Yong TS. Association between sociodemographic factors and diarrhea in children under 5 years in Rwanda. *The Korean journal of parasitology*. 2021 Feb;59(1):61. <https://doi.org/10.3347/kjp.2021.59.1.61>
5. Bardhan PK, Das R, Nahar B, Haque MA, Sobi RA, Sultana AA, et al. Assessing safety and efficacy of a novel glucose-free amino acid oral rehydration solution for watery diarrhea management in children: a randomized, controlled, phase III trial. *Eclinicalmedicine*. 2024 Jun 1;72.
6. Huang R, Xing HY, Liu HJ, Chen ZF, Tang BB. Efficacy of probiotics in the treatment of acute diarrhea in children: a systematic review and meta-analysis of clinical trials. *Transl Pediatr*. 2021;10(12):3248-3260. <https://doi.org/10.21037/tp-21-511>.
7. Szajewska H, Kołodziej M, Zalewski BM. Systematic review with meta-analysis: *Saccharomyces boulardii* for treating acute gastroenteritis in children-a 2020 update. *Aliment Pharmacol Ther*. 2020;51(7):678-688. <https://doi.org/10.1111/apt.15659>.
8. Barakat SH, Meheissen MA, Omar OM, Elbana DA. Bovine Colostrum in the Treatment of Acute Diarrhea in Children: A Double-Blinded Randomized Controlled Trial. *J Trop Pediatr*. 2020;66(1):46-55. <https://doi.org/10.1093/tropej/fmz029>.
9. Playford RJ, Weiser MJ. Bovine colostrum: Its constituents and uses. *Nutrients*. 2021 Jan 18;13(1):265. <https://doi.org/10.3390/nu13010265>
10. Chandwe K, Kelly P. Colostrum Therapy for Human Gastrointestinal Health and Disease. *Nutrients*. 2021;13(6):1956. <https://doi.org/10.3390/nu13061956>.
11. Yalçintaş YM, Duman H, Rocha JM, Bartkiene E, Karav S, OZOGUL F. Role of bovine colostrum against various diseases. *Food Bioscience*. 2024 Aug 2;104818. <https://doi.org/10.1016/j.fbio.2024.104818>
12. Hajjhashemi P, Haghighatdoost F, Kassaian N, Rahim Khorasani M, Hoveida L, Nili H, Tamizifar B, Adibi P. Therapeutics effects of bovine colostrum applications on gastrointestinal diseases: a systematic review. *Systematic Reviews*. 2024 Feb 26;13(1):76. <https://doi.org/10.1186/s13643-024-02489-1>.
13. Suwarba IG, Sudaryat S, Hendra S, Suandi IK, Widiana R. The role of bovine colostrum on recovery time and length of hospital stay of acute diarrhea in infants and children: a double-blind randomized controlled trial. *Paediatr Indones*. 2006;46(3):127-33.
14. Sangild PT, Vonderohe C, Melendez Heib V, Burrin DG. Potential Benefits of Bovine Colostrum in Pediatric Nutrition and Health. *Nutrients*. 2021 Jul 26;13(8):2551. <https://doi.org/10.3390/nu13082551>.
15. Chandwe K, Kelly P. Colostrum Therapy for Human Gastrointestinal Health and Disease. *Nutrients*. 2021 Jun 7;13(6):1956. <https://doi.org/10.3390/nu13061956>.
16. Sadeghirad B, Morgan RL, Zeraatkar D, Zea AM, Couban R, Johnston BC, Florez ID. Human and Bovine Colostrum for Prevention of Necrotizing Enterocolitis: A Meta-analysis. *Pediatrics*. 2018 Aug;142(2):e20180767. <https://doi.org/10.1542/peds.2018-0767>.

17. Barakat NM. Gut priming with bovine colostrum and T regulatory cells in preterm neonates: a randomized controlled trial. *Pediatr Res*. 2021 Sep;90(3):650-656. <https://doi.org/10.1038/s41390-020-01344-y>.
18. Halasa M, Zydecka KS, Machalinski B, Buhner L, Halasa MB. Six Weeks of Supplementation with Bovine Colostrum Effectively Reduces URTIs Symptoms Frequency and Gravity for Up to 20 Weeks in Pre-School Children. *Nutrients*. 2023 Aug 18;15(16):3626. <https://doi.org/10.3390/nu15163626>
19. Li J, Xu YW, Jiang JJ, Song QK. Bovine colostrum and product intervention associated with relief of childhood infectious diarrhea. *Scientific Reports*. 2019 Feb 28;9(1):3093. <https://doi.org/10.1038/s41598-019-39644-x>
20. Linehan K, Ross RP, Stanton C. Bovine colostrum for veterinary and human health applications: A critical review. *Annual Review of Food Science and Technology*. 2023 Mar 27;14(1):387-410. <https://doi.org/10.1146/annurev-food-060721-014650>